Last update: Jan. 1, 2021

Mometasone Furoate

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Corticosteroid for topical cutaneous, intranasal or inhaled application.
Indicated in the treatment of asthma, allergic rhinitis and atopic dermatitis, psoriasis and contact eczema.
Authorized use in Pediatrics from 3 years (rhinitis) and 12 years (asthma).

At the date of this last update we did not find published data on its excretion in breast milk.

Mometasone furoate is poorly absorbed after inhalation, intranasal use, and topical application (< 1%).

Its pharmacokinetic characteristics (low systemic absorption, moderately elevated molecular weight, high plasma protein binding, high pKa and large volume of distribution, make it very unlikely its excretion into breast milk in significant amounts.

Its very low oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk.

Several medical societies, experts and expert consensus, consider the use of this medication to be safe and compatible with breastfeeding (Middleton 2020, National Asthma EPP 2004).

TOPICAL USE:
When used for treatment of eczema or dermatitis of the nipple, it should be preferred a lower-potency steroid together with application just after a feed in order to let the medication has disappeared before the next meal. Otherwise, wipe-out excess of cream by using a cotton gauze and avoid a continuous use for longer than one week.

Reportedly, one case of mineral-steroid toxicity occurred after a prolonged use on the nipple (De Stefano 1983).

It is advisable to avoid the application to the nipple of creams, gels and other topical products containing paraffin (mineral oil) so that the infant does not absorb them (Concin 2008, Noti 2003).

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0,1 - 1 %
Molecular weight 427 daltons
Protein Binding 98 %
VD 4,7 l/Kg
pKa 12,49 -
T1/2 4,5 - 5,6 hours

References

  1. Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, Johnson B, Albrechtsen C, Edenborough F, Rigau D, Gibson PG, Backer V. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020 Feb 6;55(2). pii: 1901208. Abstract Full text (link to original source) Full text (in our servers)
  2. MSD. Mometasona inhalada. Ficha técnica 2020 Full text (link to original source) Full text (in our servers)
  3. Merck. Mometasona, nasal. Drug summary 2018 Full text (in our servers)
  4. PDR.net Mometasona tópica Drug summary 2014 Abstract Full text (in our servers)
  5. Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Fessler S, Windbichler G, Zeimet A, Ulmer H, Siegl H, Rieger K, Concin H, Grob K. Mineral oil paraffins in human body fat and milk. Food Chem Toxicol. 2008 Abstract
  6. AEMPS Mometasona Tópica Ficha técnica 2007 Abstract Full text (in our servers)
  7. National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. 2004;1-57. 2004 Full text (link to original source) Full text (in our servers)
  8. Noti A, Grob K, Biedermann M, Deiss U, Brüschweiler BJ. Exposure of babies to C15-C45 mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003 Abstract
  9. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)
  10. De Stefano P, Bongo IG, Borgna-Pignatti C, Severi F. Factitious hypertension with mineralocorticoid excess in an infant. Helv Paediatr Acta. 1983 Abstract

Total visits

64,920

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM